Clinical Trials Logo

Obesity clinical trials

View clinical trials related to Obesity.

Filter by:

NCT ID: NCT05942586 Recruiting - Obesity Clinical Trials

The Symbiont-Restore Study

Start date: May 22, 2023
Phase: N/A
Study type: Interventional

Within the framework of the Science Foundation Ireland funded Microbe Restore Project, the Symbiont Restore Study is an Investigator-initiated trial which explores the prospective health advantages associated with a particular bacterium known as Limosilactobacillus reuteri (L. reuteri) PB-W1™. In the Symbiont Restore Study, we seek to determine if supplementation with L. reuteri PB-W1™, can beneficially alter the composition and function of the gut microbiome, particularly in terms of immunomodulatory benefits, intestinal health, satiety, as well as markers of psychological stress and sleep quality. Additionally, this study will explore whether combining this strain with a prebiotic blend of dietary fibres (comprising 50 % raffinose and 50 % xylooligosaccharide) through a "synbiotic" approach can enhance its therapeutic benefits.

NCT ID: NCT05942287 Recruiting - Obesity Clinical Trials

The Effect of Obesity and Weight Loss in Heart Failure With Reduced Ejection Fraction.

SLEnDR
Start date: May 24, 2023
Phase: N/A
Study type: Interventional

This study looks at the effects of weight loss in people who have heart failure with reduced ejection fraction (HFpEF) and are overweight or obese. The main questions it aims to answer are whether weight loss in this group of people improves: - The heart's shape and how well it pumps blood - The person's quality of life and how much they can exercise Participants will attend 2 study visits, separated by 3-6 months. The intervention period takes place in between the 2 study visits. Each study visit may involve measurements including: Symptom and quality of life questionnaires Body measurements such as height and weight Blood tests Ultrasound scans of the heart (echocardiogram) Magnetic Resonance Imaging (MRI) scans of the heart 6 minute walk test Participants are randomly allocated (in other words, by lottery) to either 'diet' or 'control' groups. The control group will continue standard care. The diet group will be enrolled in a weight loss program supervised by the study team. Participants in the diet group will replace their usual meals with meal replacement products specifically designed to deliver a low calorie diet for weight loss. The products will consist of formula soups, shakes and porridges. This diet would last 8 weeks, followed by a guided period of food reintroduction and maintenance.

NCT ID: NCT05936385 Recruiting - Obesity Clinical Trials

Mobile Integrated Care for Childhood Obesity

Start date: July 26, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate a new way of providing healthcare to children with an unhealthy weight. Families who participate will be assigned by chance to one of two groups. One group will see their child's primary care provider to talk about healthy lifestyles for 6 months. The other group will be in our Healthy Lifestyle program for 6 months. This will include: - Check-ins with lifestyle specialists and community health workers, - A mobile app to help support a healthy lifestyle, and - Access to community programs and activities. The main questions the study aims to answer are: - Do children in the Healthy Lifestyle program have better weight outcomes? - Do more families in the Healthy Lifestyle program stay in the study? - Does the Healthy Lifestyle program work better for families from certain communities?

NCT ID: NCT05936151 Recruiting - Type 2 Diabetes Clinical Trials

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Start date: July 20, 2023
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will lasts around 31 weeks.

NCT ID: NCT05935514 Recruiting - Obesity Clinical Trials

Improving Glycemic Control Using a Virtual Weight Control Program and Continuous Glucose Monitoring

VITAL-CGM
Start date: August 22, 2023
Phase: N/A
Study type: Interventional

This study is a randomized clinical trial with the primary aim examining the efficacy of a novel integrated solution of a digitally delivered behavioral weight management program tailored for diabetes utilizing a continuous glucose monitor (CGM) built into the WW digital platform for adults with type 2 diabetes (T2D) for the reduction of HbA1c.

NCT ID: NCT05933707 Recruiting - Obesity Clinical Trials

Small Extracellular Vesicles and Insulin Action

SEV
Start date: June 14, 2023
Phase: N/A
Study type: Interventional

The goals of this research study are to: 1) understand why some people with obesity are protected from developing conditions such as type 2 diabetes and cardiovascular disease while others are more likely to develop obesity-related conditions; 2) assess the effect of small extracellular vesicles (sEVs also called exosomes), obtained from human participants, on metabolic function in cultured cells and in mice.

NCT ID: NCT05931939 Recruiting - Obesity Clinical Trials

Laparoscopic Ileal Interposition and Weight Regain

Start date: December 1, 2023
Phase: N/A
Study type: Interventional

The investigators will study the Ileal interposition to the treatment of weight regain after Roux-en-Y gastric bypass, assessing weight loss, body composition, quality of life, metabolic biomarkers, inflammatory biomarkers, and incretin hormones

NCT ID: NCT05931367 Recruiting - Obesity Clinical Trials

A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

TRIUMPH-4
Start date: August 1, 2023
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight and have osteoarthritis (OA) of the knee. The study will lasts about 77 weeks.

NCT ID: NCT05929079 Recruiting - Obesity Clinical Trials

A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

TRIUMPH-2
Start date: July 11, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.

NCT ID: NCT05929066 Recruiting - Obesity Clinical Trials

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

TRIUMPH-1
Start date: July 10, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits.